Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 9.28B -14.1% |
| Revenue (ttm) | 1.43B +92.8% |
| Net Income | -155.46M |
| EPS | -6.73 |
| Shares Out | 23.23M |
| PE Ratio | n/a |
| Forward PE | 76.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,088,724 |
| Open | 400.00 |
| Previous Close | 400.10 |
| Day's Range | 378.28 - 401.61 |
| 52-Week Range | 353.54 - 615.00 |
| Beta | -1.00 |
| Analysts | Strong Buy |
| Price Target | 688.94 (+72.39%) |
| Earnings Date | Nov 3, 2026 |
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price target is $688.94, which is an increase of 72.39% from the latest price.
News
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G...
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today anno...
Madrigal Pharmaceuticals announces real-world data on rezdiffra
Madrigal Pharmaceuticals (MDGL) announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases The Liver Meeting, taking place No...
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals price target raised to $743 from $709 at Truist
Truist raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $743 from $709 and keeps a Buy rating on the shares. The company reported a robust Q3, with lead…
Madrigal Pharmaceuticals price target raised to $633 from $612 at Canaccord
Canaccord raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $633 from $612 and keeps a Buy rating on the shares. The firm said Madrigal reported financial results and…
H.C. Wainwright questions whistleblower allegations against Madrigal
H.C. Wainwright says says Madrigal Pharmaceuticals (MDGL) shares dropped 8% last night due to recent litigation activity regarding a complaint by a former employee under the whistleblower-protection p...
Madrigal discloses former employee filed whistleblower complaint
In the company’s 10-Q quarterly regulatory filing, Madrigal Pharmaceuticals (MDGL) disclosed: “On October 9, 2026, a former employee filed a complaint against the Company in the United States District...
Madrigal Pharmaceuticals price target raised to $760 from $725 at Citi
Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $760 from $725 and keeps a Buy rating on the shares after “another strong quarter” for Rezdiffra. The timing…
Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 sales rose 50% YoY to $431.3 million, with $55.4 million net income and more than 55,850 active patients. Market growth and F4c trials underpin expansion, while management expects continued investment and near-term earnings variability.
Madrigal Pharmaceuticals Earnings release: Q3 2026
Madrigal Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Madrigal Pharmaceuticals Slides: Q3 2026
Madrigal Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Madrigal Pharmaceuticals Quarterly report: Q3 2026
Madrigal Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Madrigal Pharmaceuticals reports Q3 EPS $1.83, consensus ($1.09)
Reports Q3 revenue $431.27M, consensus $405.12M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening p...
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals management to meet with Citizens
Meeting to be held in Denver on November 5 hosted by Citizens.
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatm...
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3,...
Madrigal Pharmaceuticals price target lowered to $533 from $543 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $533 from $543 and keeps a Neutral rating on the shares. The firm updated estimates ahead…
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals price target raised to $735 from $669 at UBS
UBS raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $735 from $669 and keeps a Buy rating on the shares.
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, ...
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and $704 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outper...
Madrigal Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and $725 price target The firm believes the company’s Rezdiffra is being underappreciated at current share levels. The laun...
Madrigal Pharmaceuticals management to meet with Oppenheimer
Meeting to be held in Dallas on September 25 hosted by Oppenheimer.